×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ALNY – alnylam pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ALNY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/19
11:41 am
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at William Blair.
11/19
07:48 am
alny
Biodefense Global Industry Overview 2021-2030: AI and Machine Learning to Revolutionize Early Detection and Response [Yahoo! Finance]
Low
Report
Biodefense Global Industry Overview 2021-2030: AI and Machine Learning to Revolutionize Early Detection and Response [Yahoo! Finance]
11/18
01:35 pm
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.
Low
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.
11/18
01:35 pm
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $296.00 price target on the stock.
Low
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $296.00 price target on the stock.
11/18
10:40 am
alny
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study [Yahoo! Finance]
Low
Report
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study [Yahoo! Finance]
11/18
06:26 am
alny
High Growth Tech Stocks To Watch This November 2024 [Yahoo! Finance]
Low
Report
High Growth Tech Stocks To Watch This November 2024 [Yahoo! Finance]
11/18
05:30 am
alny
High Growth Tech Stocks to Watch in November 2024 [Yahoo! Finance]
Low
Report
High Growth Tech Stocks to Watch in November 2024 [Yahoo! Finance]
11/18
04:37 am
alny
High Growth Tech Stocks To Explore In November 2024 [Yahoo! Finance]
Low
Report
High Growth Tech Stocks To Explore In November 2024 [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
10/31/2024
08:00 am
ALNY
alnylam pharmaceuticals, inc.
BEAT
Report
-0.2%
alnylam pharmaceuticals, inc.
8/1/2024
08:00 am
ALNY
alnylam pharmaceuticals, inc.
BEAT
Report
12.5%
alnylam pharmaceuticals, inc.
5/2/2024
08:00 am
ALNY
alnylam pharmaceuticals, inc.
BEAT
Report
-0.3%
alnylam pharmaceuticals, inc.
2/15/2024
08:00 am
ALNY
alnylam pharmaceuticals, inc.
BEAT
Report
-10.2%
alnylam pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/12
09:51 am
alny
Form SC 13G/A ALNYLAM PHARMACEUTICALS, Filed by: FMR LLC
Low
Report
Form SC 13G/A ALNYLAM PHARMACEUTICALS, Filed by: FMR LLC
11/8
10:35 am
alny
Form SC 13G/A ALNYLAM PHARMACEUTICALS, Filed by: WELLINGTON MANAGEMENT GROUP LLP
Low
Report
Form SC 13G/A ALNYLAM PHARMACEUTICALS, Filed by: WELLINGTON MANAGEMENT GROUP LLP
10/31
08:23 am
alny
Form 10-Q ALNYLAM PHARMACEUTICALS, For: Sep 30
Low
Report
Form 10-Q ALNYLAM PHARMACEUTICALS, For: Sep 30
10/31
08:11 am
alny
Form 8-K ALNYLAM PHARMACEUTICALS, For: Oct 31
Low
Report
Form 8-K ALNYLAM PHARMACEUTICALS, For: Oct 31
10/10
04:06 pm
alny
Form 4 ALNYLAM PHARMACEUTICALS, For: Oct 08 Filed by: Garg Pushkal
Low
Report
Form 4 ALNYLAM PHARMACEUTICALS, For: Oct 08 Filed by: Garg Pushkal
10/3
04:12 pm
alny
Form 4 ALNYLAM PHARMACEUTICALS, For: Oct 01 Filed by: Hesslein Robert W.
Medium
Report
Form 4 ALNYLAM PHARMACEUTICALS, For: Oct 01 Filed by: Hesslein Robert W.
10/3
04:09 pm
alny
Form 3 ALNYLAM PHARMACEUTICALS, For: Sep 30 Filed by: Hesslein Robert W.
Medium
Report
Form 3 ALNYLAM PHARMACEUTICALS, For: Sep 30 Filed by: Hesslein Robert W.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/6
Form 10-Q ALNYLAM PHARMACEUTICALS, For: Jun 30
11.4%
11/19 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $128.00 price target on the stock. 10.5%
3/12 Why Alnylam Pharmaceuticals, Intuitive Surgical, and ResMed Stocks Sank Today [The Motley Fool] 9.1%
8/6 Form 8-K ALNYLAM PHARMACEUTICALS, For: Aug 06 6.3%
4/6 Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs 6.0%
11/18 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $120.00 price target on the stock. 5.6%
11/22 Form 4 ALNYLAM PHARMACEUTICALS, For: Nov 20 Filed by: Greenstreet Yvonne 5.2%
10/31 Alnylam Pharmaceuticals, Inc. 2019 Q3 - Results - Earnings Call Presentation [Seeking Alpha] 4.9%
11/26 Alnylam to Webcast Presentations at Upcoming December Investor Conferences 4.9%
2/9 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $154.00 price target on the stock. 4.8%
11/19 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $128.00 price target on the stock. 10.5%
3/12 Why Alnylam Pharmaceuticals, Intuitive Surgical, and ResMed Stocks Sank Today [The Motley Fool] 9.1%
8/6 Form 8-K ALNYLAM PHARMACEUTICALS, For: Aug 06 6.3%
4/6 Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs 6.0%
11/18 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $120.00 price target on the stock. 5.6%
11/22 Form 4 ALNYLAM PHARMACEUTICALS, For: Nov 20 Filed by: Greenstreet Yvonne 5.2%
10/31 Alnylam Pharmaceuticals, Inc. 2019 Q3 - Results - Earnings Call Presentation [Seeking Alpha] 4.9%
11/26 Alnylam to Webcast Presentations at Upcoming December Investor Conferences 4.9%
2/9 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $154.00 price target on the stock. 4.8%
TOP News Decliners
12/17
Alnylam gene-silencing therapy to treat kidney disorder succeeds in late-stage study [Reuters (UK)]
-11.7%
3/10 Alnylam Pharmaceuticals (ALNY) Presents At Barclays Global Healthcare Conference - Slideshow [Seeking Alpha] -6.9%
2/21 Form 4 ALNYLAM PHARMACEUTICALS, For: Feb 20 Filed by: MARAGANORE JOHN -6.7%
11/22 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Morgan Stanley from $124.00 to $141.00. They now have an "overweight" rating on the stock. -4.7%
4/13 Alnylam's stock surges after Blackstone confirms $2 billion investment [MarketWatch] -4.4%
9/26 Alnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference -4.3%
3/16 Alnylam shows wild action on a wild day [Seeking Alpha] -4.2%
5/3 Form SC 13G/A ALNYLAM PHARMACEUTICALS, Filed by: Sanofi -4.2%
9/6 Alnylam to Host Sixth Annual “RNAi Roundtable” Webcast Series -4.0%
1/10 Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1) -3.9%
3/10 Alnylam Pharmaceuticals (ALNY) Presents At Barclays Global Healthcare Conference - Slideshow [Seeking Alpha] -6.9%
2/21 Form 4 ALNYLAM PHARMACEUTICALS, For: Feb 20 Filed by: MARAGANORE JOHN -6.7%
11/22 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Morgan Stanley from $124.00 to $141.00. They now have an "overweight" rating on the stock. -4.7%
4/13 Alnylam's stock surges after Blackstone confirms $2 billion investment [MarketWatch] -4.4%
9/26 Alnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference -4.3%
3/16 Alnylam shows wild action on a wild day [Seeking Alpha] -4.2%
5/3 Form SC 13G/A ALNYLAM PHARMACEUTICALS, Filed by: Sanofi -4.2%
9/6 Alnylam to Host Sixth Annual “RNAi Roundtable” Webcast Series -4.0%
1/10 Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1) -3.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: